SCHEMBL1682154

SCHEMBL1682154

CCOC(=O)C(Cc1ccc(C(=O)O)cc1)C(=O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.50
ALDH1A1 P00352 3/20 0.46
TSHR P16473 1/20 0.44
MAPT P10636 1/20 0.43
EPHX2 P34913 2/20 0.42
PPARG P37231 1/20 0.42
TP53 P04637 1/20 0.42
RARB P10826 3/20 0.42
ANPEP P15144 1/20 0.42
ENPEP Q07075 1/20 0.42
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41
ACACB O00763 1/20 0.41
LDHA P00338 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1417279 0.82 MMP8 (0.47) MMP8ALDH1A1MAPTTP53NPY1R
SCHEMBL3779327 0.80 MMP8 (0.45) MMP8ALDH1A1TSHRTP53NPY1R
SCHEMBL1417367 0.79 CYP4Z1 (0.50) MMP8SMN1; SMN2
SCHEMBL13453069 0.79 MMP8 (0.44) MMP8ALDH1A1TSHRTP53NPY1R
SCHEMBL1312803 0.79 MMP8 (0.62) MMP8ALDH1A1TSHREPHX2PPARG
SCHEMBL15262696 0.77 ALDH1A1 (0.43) MMP8ALDH1A1TSHRTP53LDHA
SCHEMBL15261621 0.77 SMN1; SMN2 (0.51) MMP8ALDH1A1TSHRMAPTEPHX2
SCHEMBL15391374 0.76 MMP8 (0.60) MMP8ALDH1A1MAPTEPHX2PPARG
SCHEMBL2574638 0.75 MMP8 (0.46) MMP8ALDH1A1TSHREPHX2PPARG
SCHEMBL14491973 0.75 MMP8 (0.62) MMP8ALDH1A1TSHREPHX2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SANOFI (FR) 2012-10-25 US disclosed
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SANOFI (FR) 2012-10-25 US disclosed
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SANOFI (FR) 2012-10-25 US disclosed
EP-2482823-A2 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES SANOFI (FR) 2012-08-08 EP disclosed
WO-2011039338-A2 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES SANOFI-AVENTIS (FR) 2011-04-07 WO disclosed
WO-2011039338-A2 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASES SANOFI-AVENTIS (FR) 2011-04-07 WO disclosed
US-7820804-B2 Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof Sanofi-Aventia Deutschland GmbH (DE) 2010-10-26 US disclosed
US-7820804-B2 Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof Sanofi-Aventia Deutschland GmbH (DE) 2010-10-26 US disclosed
US-7820804-B2 Fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof Sanofi-Aventia Deutschland GmbH (DE) 2010-10-26 US disclosed
EP-1758914-B1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2007-11-21 EP disclosed
EP-1758914-B1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2007-11-21 EP disclosed
US-20070197623-A1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
US-20070197623-A1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
US-20070197623-A1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
EP-1758914-A1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF Sanofi-Aventis Deutschland GmbH (DE) 2007-03-07 EP disclosed
WO-2005121161-A1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270819-A1 USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE SLC5A1, SLC5A2, SOST MMP8 1200/4885ALDH1A1 855/4885TSHR 3106/4885
US-20070197623-A1 NOVEL FLUOROGLYCOSIDE DERIVATIVES OF PYRAZOLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THE USE THEREOF DPP4, UGGT1, SLC5A2 MMP8 3989/4885ALDH1A1 1534/4885TSHR 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.